RELATIONSHIP BETWEEN VALPROIC ACID DOSAGE, PLASMA-CONCENTRATION AND CLEARANCE IN ADULT MONOTHERAPY PATIENTS WITH EPILEPSY

被引:34
作者
GIDAL, BE
PITTERLE, ME
SPENCER, NW
MALY, MM
机构
[1] UNIV WISCONSIN,DEPT NEUROL,MADISON,WI 53706
[2] UNIV WISCONSIN,COMPREHENS EPILEPSY PROGRAMME,MADISON,WI
关键词
D O I
10.1111/j.1365-2710.1995.tb00651.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Significant variability has been reported in the plasma concentration-dose relationship for the anticonvulsant compound valproic acid (VPA). Several factors may contribute to this observed variability, including heterogeneous patient populations of children and adults, polytherapy, and timing of plasma concentration sampling. To optimally determine the relationship between trough VPA plasma concentration and dose, we evaluated a homogeneous group of adult ambulatory patients with epilepsy receiving VPA monotherapy. Furthermore, we sought to evaluate whether a relationship existed between VPA dosage and plasma clearance for both total and unbound or free drug. Steady-state trough plasma concentrations were determined in thirty-two patients. Mean VPA dose was 22.8 +/- 10.3 mg/kg/day. Mean total and unbound VPA plasma concentrations were 97.9 +/- 34.9 and 13.2 +/- 10.6 mu g/ml, respectively, Significant correlations between VPA dose and total and unbound plasma concentrations were found (r = 0.82 and r = 0.85, P less than or equal to 0.001, respectively). Significant relationships were also observed between VPA dose and clearance. A positive correlation was noted for dose and total plasma clearance (r = 0.61, P less than or equal to 0.001), while an inverse correlation existed between dose and unbound VPA plasma clearance (r = 0.51, P < 0.01). Although a statistically significant correlation does exist between VPA dosage and both total and unbound plasma concentrations, significant interpatient variability still remains even under 'optimal' therapeutic drug monitoring conditions.
引用
收藏
页码:215 / 219
页数:5
相关论文
共 17 条
[1]   EFFECT OF VALPROATE DOSE ON FORMATION OF HEPATOTOXIC METABOLITES [J].
ANDERSON, GD ;
ACHEAMPONG, AA ;
WILENSKY, AJ ;
LEVY, RH .
EPILEPSIA, 1992, 33 (04) :736-742
[2]   VALPROIC ACID CLEARANCE - UNBOUND FRACTION AND DIURNAL-VARIATION IN YOUNG AND ELDERLY ADULTS [J].
BAUER, LA ;
DAVIS, R ;
WILENSKY, A ;
RAISYS, V ;
LEVY, RH .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1985, 37 (06) :697-700
[3]   VALPROIC ACID DOSAGE AND PLASMA-PROTEIN BINDING AND CLEARANCE [J].
BOWDLE, TA ;
PATEL, IH ;
LEVY, RH ;
WILENSKY, AJ .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1980, 28 (04) :486-492
[4]  
BRUNI J, 1978, CLIN PHARMACOL THER, V24, P324
[5]   PHARMACOKINETICS OF VALPROIC ACID IN CHILDREN .1. MULTIPLE ANTI-EPILEPTIC DRUG-THERAPY [J].
CLOYD, JC ;
KRIEL, RL ;
FISCHER, JH ;
SAWCHUK, RJ ;
EGGERTH, RM .
NEUROLOGY, 1983, 33 (02) :185-191
[6]   VALPROIC ACID PHARMACOKINETICS IN CHILDREN .4. EFFECTS OF AGE AND ANTIEPILEPTIC DRUGS ON PROTEIN-BINDING AND INTRINSIC CLEARANCE [J].
CLOYD, JC ;
FISCHER, JH ;
KRIEL, RL ;
KRAUS, DM .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1993, 53 (01) :22-29
[7]   VARIABLE FREE AND TOTAL VALPROIC ACID CONCENTRATIONS IN SOLE-DRUG AND MULTIDRUG THERAPY [J].
CRAMER, JA ;
MATTSON, RH ;
BENNETT, DM ;
SWICK, CT .
THERAPEUTIC DRUG MONITORING, 1986, 8 (04) :411-415
[8]   VALPROIC ACID - INVITRO PLASMA-PROTEIN BINDING AND INTERACTION WITH PHENYTOIN [J].
CRAMER, JA ;
MATTSON, RH .
THERAPEUTIC DRUG MONITORING, 1979, 1 (01) :105-116
[9]   PHARMACOLOGY OF VALPROIC ACID IN CHILDREN WITH SEVERE EPILEPSY - CLEARANCE AND HEPATOTOXICITY [J].
DODSON, WE ;
TASCH, V .
NEUROLOGY, 1981, 31 (08) :1047-1050
[10]   APPARENT VALPROIC ACID NEUROTOXICITY IN A HYPOALBUMINEMIC PATIENT [J].
GIDAL, BE ;
COLLINS, DM ;
BEINLICH, BR .
ANNALS OF PHARMACOTHERAPY, 1993, 27 (01) :32-35